# Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

> **NCT06202625** · PHASE2,PHASE3 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 142 (estimated)

## Conditions studied

- Thrombocytopenia
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** avatrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06202625
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2024-10-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202625, "Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06202625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*